


RealRate

PHARMACEUTICAL 2017

ABBOTT LABORATORIES Rank 11 of 292









RealRate

PHARMACEUTICAL 2017



ABBOTT LABORATORIES Rank 11 of 292

The relative strengths and weaknesses of ABBOTT LABORATORIES are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ABBOTT LABORATORIES compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 86% points. The greatest weakness of ABBOTT LABORATORIES is the variable Other Expenses, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 270%, being 268% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	26,776,000
Cost of Goods Sold	0
Intangible Assets	12,222,000
Liabilities, Current	6,660,000
Liabilities, Non-Current	0
Other Assets	7,963,000
Other Compr. Net Income	-605,000
Other Expenses	10,355,000
Other Liabilities	0
Other Net Income	-1,004,000
Other Revenues	20,853,000
Property and Equipment	5,705,000
Research and Development	1,422,000
Selling, General and Administrative Expense	6,672,000

Output Variable	Value in 1000 USD
Assets	52,666,000
Liabilities	6,660,000
Expenses	18,449,000
Revenues	20,853,000
Stockholders Equity	46,006,000
Net Income	1,400,000
Comprehensive Net Income	1,097,500
Economic Capital Ratio	270%

